ProShare Advisors’s Organogenesis Holdings ORGO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-12,483
Closed -$64.7K 1978
2025
Q4
$64.7K Buy
12,483
+804
+7% +$3.9K ﹤0.01% 1929
2025
Q3
$49.3K Sell
11,679
-2,326
-17% -$10.8K ﹤0.01% 1936
2025
Q2
$51.3K Sell
14,005
-814
-5% -$3.03K ﹤0.01% 1991
2025
Q1
$64K Sell
14,819
-5,510
-27% -$22.2K ﹤0.01% 1919
2024
Q4
$65.1K Buy
20,329
+6,689
+49% +$22.4K ﹤0.01% 2146
2024
Q3
$39K Buy
+13,640
New +$38.3K ﹤0.01% 2003
2024
Q2
Sell
-12,620
Closed -$35.8K 1956
2024
Q1
$35.8K Buy
12,620
+995
+9% +$3.38K ﹤0.01% 1945
2023
Q4
$47.5K Buy
+11,625
New +$32.6K ﹤0.01% 1868
2023
Q1
Sell
-11,192
Closed -$30.1K 1878
2022
Q4
$30.1K Buy
+11,192
New +$32.6K ﹤0.01% 1781
2022
Q2
Sell
-15,211
Closed -$117K 2022
2022
Q1
$117K Buy
15,211
+4,905
+48% +$38K ﹤0.01% 2002
2021
Q4
$95K Buy
+10,306
New +$109K ﹤0.01% 2212
2021
Q3
Sell
-11,253
Closed -$187K 2185
2021
Q2
$187K Buy
+11,253
New +$210K ﹤0.01% 2162

Other funds holding ORGO

ProShare Advisors's ORGO Position: Q1 2026 in Review

ProShare Advisors sold out of Organogenesis Holdings (ORGO) in Q1 2026, closing a stake of 12,483 shares — an estimated $64.7K sold.

ProShare Advisors first reported a position in ORGO in Q2 2021 and held it in 12 quarters. The position peaked at $187K in Q2 2021. 121 funds tracked by Wall St. Rank hold ORGO as of Q1 2026.

  • ProShare Advisors reported no remaining Organogenesis Holdings position as of Q1 2026 after selling out during the quarter.
  • ProShare Advisors sold 12,483 Organogenesis Holdings shares in Q1 2026, an estimated $64.7K.
  • ProShare Advisors first reported a position in Organogenesis Holdings in Q2 2021 and held it in 12 quarters.
  • ProShare Advisors's Organogenesis Holdings position peaked at $187K in Q2 2021.
  • 121 funds tracked by Wall St. Rank held Organogenesis Holdings as of Q1 2026.

Based on ProShare Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.